Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
"OPL 245 – RDS plc informed of DPP preparing to prosecute"
https://www.investegate.co.uk/royal-dutch-shell--rdsa-/prn/opl-245---rds-plc-informed-of-dpp-preparing-to-prosecute/20190301070000PC34B/
https://www.investegate.co.uk/yourgene-health-plc/rns/holding-s--in-company/201902261521411837R/
Article by Phil Oakley of Investors Chronicle on why good companies need growth.
"Bioventix makes antibodies for use in medical testing. In many ways it is an investor’s dream business. It sells its antibodies to medical testing machine companies such as Siemens or Roche. Every time a Bioventix antibody is used in a blood test it receives a royalty. These royalties are small, but with millions of tests done every year they add up to a meaningful amount of money.
The great thing about Bioventix is that it is such a small company, with its products being developed by just a few people working out of a laboratory in Surrey. Virtually all its sales growth over the past five years has fed through to operating profits and has helped to create an exceptionally profitable business.
The investment needed to grow has been minimal with the increase in capital employed almost entirely attributable to the company’s rising cash balance. There are high hopes for its troponin antibody which can reveal if someone has had a heart attack. Competition is a concern from other types of antibody, but growth from new products could see big growth in future profits and cash flows that need little extra investment."
--> beatrootjuice:
Hi, Are you aware of the Times article over the weekend covering
H2B? It made most of the housebuilders have a small wobble yesterday.
I noticed it gave some holders the chance to top up sub 2300p !
Cheers, Hugh.
https://www.investegate.co.uk/yourgene-health-plc/rns/holding-s--in-company/201902220805075871Q/
Just 'tweeking' their position....
LPLDL® determined GRAS by an Expert Panel in US
https://www.investegate.co.uk/optibiotix-health--opti-/rns/lpldl--determined-gras-by-an-expert-panel-in-us/201902210700026638Q/
Another step forwards...
From GL: Will keep us informed as updates occur... thank you for attending the broadcast.
" I'll get my coat"...:-)
Graham Lumsden just started speaking now.....
As limited as it may be, after 6 days (counting the W/E).
With the share price where it is. Was hoping for something better
than a re-hash of the limited stuff announced thus far.
OR.... Are the poor dears still "in shock" ?
"...recent events that Motif has announced and the Company's plans."
AND...
"No new material information will be disclosed during the call"
"Company will hold a conference call on
Tuesday, February 19, 2019: at 8:30 AM ET/1:30 PM GMT/2:30 PM CET.
Prudential and Invesco... both reduced their holdings.
What do they know?
https://www.investegate.co.uk/plus500-ltd--plus-/rns/holding-s--in-company/201902131405189307P/
https://www.investegate.co.uk/optibiotix-health--opti-/rns/trading-statement/201902130700028120P/
Assuming the four divis for 2019 are 80p in total (again).
On a share price of 1545p that equates to +5.17799%.
I thank yaww ;-)
" SlImBiome® Medical agreement for Greece and Cyprus "
https://www.investegate.co.uk/optibiotix-health--opti-/rns/slimbiome--medical-agreement-for-greece-and-cyprus/201812040700032850J/
Long way down from the March 2018 Placing @11p.
Is there any 'rainbow' in todays RNS to move the SP or are we heading
down towards the previous August 2017 Placing @4.3p?
With my average, I'm still in profit surprisingly.
Looks like another year or three, of patience is required.
"We are on track to deliver full year 2018 results in line with our expectations, and subject to shareholder approval, we reiterate our commitment to return £600 million by way of total dividend to shareholders in 2019, a 20% increase on 2018."
Dividends:
"The Board currently intends to propose a total dividend of 15.07 eurocents per share for the current financial year, in-line with the FY18 dividend, with an interim dividend of 4.84 eurocents (also stable YoY). The Board will consider growing the dividend per share over the long-term, once the Group's financial leverage has reduced towards the lower end of the revised target range of 2.5x-3.0x net debt / EBITDA. "